Submission of Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has filed its Annual Secretarial Compliance Report for FY25, as required under SEBI's listing rules. The report, certified by Practicing Company Secretary A. Mohan Rami Reddy, confirms that the company has complied with all applicable SEBI regulations during the review period, with no deviations, fines, or penalties. The company has adopted and timely updated all required policies, maintained proper disclosures on its website, followed secretarial standards, and obtained audit committee approval for related-party transactions. No action was taken against the company, its directors, promoters, or subsidiaries by SEBI or stock exchanges during the year. A long-pending insider trading matter continues against some promoters (not the company) related to trades done in 2008-09 during the Pfizer licensing deal; this was settled in 2020 with payments of Rs.22 million by the company and Rs.198.2 million by promoters, but a dispute over calculation errors in the settlement amount is pending before the Telangana High Court.
This is a routine annual compliance filing with a clean report — no new regulatory action against the company and no impact on shareholders. The only open matter is against individual promoters and does not affect the company directly.